ELISA Kit for Cholecystokinin (CCK) Canis familiaris; Canine (Dog) Competition ELISA

CCK-PZ

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • ELISA Kit for Cholecystokinin (CCK) Packages (Simulation)
  • ELISA Kit for Cholecystokinin (CCK) Packages (Simulation)
  • ELISA Kit for Cholecystokinin (CCK) Results demonstration
  • CEA802Ca.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Cholecystokinin (CCK) and the recovery rates were calculated by comparing the measured value to the expected amount of Cholecystokinin (CCK) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 79-94 83
EDTA plasma(n=5) 79-91 81
heparin plasma(n=5) 85-94 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cholecystokinin (CCK) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cholecystokinin (CCK) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cholecystokinin (CCK) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 94-104% 78-101% 80-102% 94-105%
EDTA plasma(n=5) 83-102% 78-101% 98-105% 95-105%
heparin plasma(n=5) 92-99% 86-101% 85-103% 89-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1 Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Reagent Diluent 1×300µL Stop Solution 1×6mL
TMB Substrate 1×9mL Instruction manual 1
Wash Buffer (30 × concentrate) 1×20mL

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
    And then add 50µL prepared Detection Reagent A immediately.
    Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
7. Add 50µL Stop Solution. Read at 450 nm immediately.

ELISA Kit for Cholecystokinin (CCK)

Test principle

This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Cholecystokinin (CCK) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Cholecystokinin (CCK) and unlabeled Cholecystokinin (CCK) (Standards or samples) with the pre-coated antibody specific to Cholecystokinin (CCK). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Cholecystokinin (CCK) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Cholecystokinin (CCK) in the sample.

Citations

  • Disturbed release of cholecystokinin in pregnant women with hyperemesis gravidarumPubmed:25331205
  • Effects of sphincter of Oddi motility on the formation of cholesterol gallstonesPubmed:27350732
  • Luhong formula inhibits myocardial fibrosis in a paracrine manner by activating thegp130/JAK2/STAT3 pathway in cardiomyocytes.pubmed:28115285
  • Cholecystokinin Expression in the Development of Postinfarction Heart Failure.pubmed:29130944
  • Assessment of the role of cholecystokinin in hyperemesis gravidarum and correlation with its severity:
  • Effects of dietary leucine and phenylalanine on pancreas development, enzyme activity, and relative gene expression in milk-fed Holstein dairy calvesPubmed:29477524
  • Alignments of endocrine, anthropometric, and metabolic parameters in type 2 diabetes after intervention with an Okinawa-based Nordic dietPubmed:29599686
  • The Relationship of Appetite-Regulating Hormones in the Development of Cardiac CachexiaPubmed: 30799377
  • Hejie Zhitong prescription promotes sleep and inhibits nociceptive transmission-associated neurotransmitter activity in a rodent migraine modelPubmed: 33014123
  • Appetite and Satiety Effects of the Acute and Regular Consumption of Green Coffee Phenols and Green Coffee Phenol/Oat β-Glucan Nutraceuticals in Subjects with …34828792
  • The microbiota-gut-kidney axis mediates host osmoregulation in a small desert mammalPubmed:35379849
  • Digestion characteristics of quinoa, barley and mungbean proteins and the effects of their simulated gastrointestinal digests on CCK secretion in enteroendocrine STC …Pubmed:35587126

Recommend products